Current Trends in the Management of Adamantinoma of Long Bones

Qureshi, Abid; Shott, Susan; Mallin, Bruce A.; Gitelis, Steven

doi:10.2106/00004623-200008000-00009

Cited by 109 publications

(118 citation statements)

References 35 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…[3] Qureshi ve arkadaşlarının yaptığı çalışmada, uzuv kurtarma oranı %84 ve 10-yıllık sağkalım oranı %87,2 olarak bildirilmiştir. [4] Uzun kemiklerin diyafizini tutması nedeniyle genellikle interkaler rezeksiyon uygulanır. İnterkaler defektin köprülenmesi, biyolojik veya non-biyolojik rekonstrük-siyon [5] yöntemleri ile yapılabilir, ancak tercih edilmesi gereken yöntem biyolojik rekonstrüksiyondur.…”

Section: Tedaviunclassified

“…Rekonstrüksiyona bağlı komplikasyon oranları yük-sek olarak rapor edilmektedir [4,6] ancak biz bunun uygulanan rekonstrüktif yöntemlerin eksikliklerine bağlı olduğu kanısındayız. Özellikle uzun segmentlerde tek başına masif allogreft kullanımının biyolojik olarak yetersiz olduğunu ve bu nedenle uzun kemik interkaler defekt rekonstrüksiyonunda serbest damarlı fibula grefti ile kombine edilmiş masif greft kullanılması gerektiğini düşünüyoruz.…”

Section: Tedaviunclassified

See 1 more Smart Citation

Nadir görülen habis kemik tümörlerine yaklaşım: Adamantinoma ve kordomanın tanı ve tedavi özellikleri

Özger¹

2014

TOTBID

View full text Add to dashboard Cite

Section: Tedaviunclassified

Nadir görülen habis kemik tümörlerine yaklaşım: Adamantinoma ve kordomanın tanı ve tedavi özellikleri

Özger¹

2014

TOTBID

View full text Add to dashboard Cite

“…The 10-year local recurrence rate is 18.6%. (8) The clinical presentation is progressive volumetric increase accompanied by local pain, and history of trauma is common. (9) In our two cases, the symptoms were benign and were associated with the history of local trauma, which made the patients postpone seeking treatment.…”

Section: Casementioning

confidence: 99%

“…This procedure can delay complications such as obstructive atelectasis or hemoptysis, and, although it should only be used in exceptional cases, we recommend its use for the treatment of cases in which there is no therapeutic alternative to surgery, such as the cases reported here. (7,8) Regarding prognosis, the literature indicates that the mean survival of patients with metastatic disease is twelve years, and that being male, having …”

Section: Casementioning

confidence: 99%

Caso raro de pneumotórax: adamantinoma metastático

et al. 2008

View full text Add to dashboard Cite

A 26-year-old Caucasian male with a history of local trauma had been experiencing an increase in left leg volume, accompanied by pain, for eight months. An X-ray of the leg revealed an osteolytic tumor in the tibial diaphysis. We performed tumor resection with histologically tumorfree margins. Seven years later, the patient presented local recurrence and underwent below-knee amputation of the affected limb. Three years later, he presented dyspnea upon moderate exertion, and, at that time, right pneumothorax was diagnosed, and nodular images, some of which were cystic, were seen in both lungs (Figure 1). Those images subsequently proved to be lung metastases of adamanti- IntroductionAdamantinoma is a rare tumor that affects long bones, and it is estimated to account for 0.1 to 0.5% of all primary bone tumors.(1) It is named for its histological similarity to the tumor of the mandible (ameloblastoma).Adamantinoma is a low-grade neoplasm that presents an indolent course, is locally aggressive, and rarely metastasizes. The secondary sites most frequently affected are the lungs, lymph nodes, and bones. When it is present in the lungs, hemoptysis can occur.Although cases of pneumothorax secondary to other metastatic tumors have been described, there are, in the literature, only three references to metastatic adamantinoma of the lung as the etiology of spontaneous pneumothorax.(2,3,4) Here, we report two cases followed by the authors. Here, we describe two cases of lung metastasis of adamantinoma of long bones, a low-grade bone neoplasm that rarely metastasizes. In both cases, the clinical presentation of the metastases was characterized by spontaneous pneumothorax secondary to tumor cavitation, a phenomenon described in only three of the studies reviewed in the literature. Clinical, radiological, and anatomopathological findings, as well as the procedures adopted in the two cases, are described.Keywords: Adamantinoma; Pneumothorax; Neoplasm metastasis; Medical records. ResumoDescrevem-se dois casos de metástases pulmonares de adamantinoma de ossos longos, o qual é uma neoplasia óssea de baixo grau que raramente metastatiza. Nos dois casos a apresentação clínica das metástases se deu por pneumotórax espontâneo secundário a escavação tumoral, fenômeno descrito em apenas três dos trabalhos consultados na literatura. São descritos os achados clínicos, radiológicos e anatomopatológicos, bem como os procedimentos adotados nos dois casos.

show abstract

“…After 5 years of first line treatment, recurrence rate is reported to be 9% and after 10 years it is 18.6% [2] . If initial excision is incomplete, recurrence rate reaches about 30%.…”

Section: Introductionmentioning

confidence: 99%

Metastatic adamantinoma responds to treatment with receptor tyrosine kinase and Aurora A kinase inhibitor

Unal

David

Dudek

2015

JST

View full text Add to dashboard Cite

Adamantinoma is to be known as the one of the least common low-grade malignant bone tumors, commonly arising in the center of long bones, mostly in the tibial mid shaft. Adamantinomas are usually managed with wide local excision and reconstruction, unless unresectable or locally recurrent. Even though adamantinomas are managed as locally aggressive tumors, they usually recur and metastasize to sites including the lymph nodes, lungs, skeleton, liver and brain. Radiotherapy and chemotherapy do not seem to be effective treatment modalities for adamantinoma; recently published case reports suggest tyrosine kinase inhibitors as an alternative therapeutic strategy. We report a case of a patient with metastatic adamantinoma who progressed after first line therapy with doxorubicin and cisplatin, and responded to pazopanib (selective multi-targeted receptor tyrosine kinase inhibitor that inhibits angiogenesis) and alisertib (small molecule Aurora A kinase inhibitor) combination therapy. Tumor response to pazopanib and alisertib in combination as a third line therapy has led us to conclude that tyrosine kinase therapy could be considered in this setting.

show abstract

Current Trends in the Management of Adamantinoma of Long Bones

Cited by 109 publications

References 35 publications

Nadir görülen habis kemik tümörlerine yaklaşım: Adamantinoma ve kordomanın tanı ve tedavi özellikleri

Nadir görülen habis kemik tümörlerine yaklaşım: Adamantinoma ve kordomanın tanı ve tedavi özellikleri

Caso raro de pneumotórax: adamantinoma metastático

Metastatic adamantinoma responds to treatment with receptor tyrosine kinase and Aurora A kinase inhibitor

Contact Info

Product

Resources

About